8-21-06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Gary L. Nelsestuen	Art Unit	: 1656
Serial No.	: 10/031,005	Examiner	: Holly G. Schnizer
Filed	: October 29, 2001	Conf. No.	: 3846
Title	: MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES		

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant requests consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: August 18, 2006

Elizabeth N. Kayton

Elizabeth N. Kayton, Ph.D.
Reg. No. 53,103

Fish & Richardson P.C.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60375696

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV710203979US

August 18, 2006
Date of Deposit

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09531-016002	Application No. 10/031,005
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))		Applicant Gary L. Nelsestuen	
		Filing Date October 29, 2001	Group Art Unit 1656

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,784,950	11/15/1988	Hagen et al.			
	AB	4,904,584	2/27/1990	Shaw			
	AC	5,041,376	8/20/1991	Gething et al.			
	AD	5,180,583	1/19/1993	Hedner			
	AE	5,225,537	7/6/1993	Foster			
	AF	5,460,950	10/24/1995	Barr et al.			
	AG	5,648,254	7/15/1997	Mulvihill et al.			
	AH	5,891,843	4/6/1999	Turecek et al.			
	AI	5,965,425	10/12/1999	Barr et al.			
	AJ	5,986,079	11/16/1999	Barr et al.			
	AK	6,013,620	1/11/2000	Turecek et al.			
	AL	6,100,061	8/8/2000	Reiter et al.			
	AM	6,423,826	7/23/2002	Nelsestuen et al.			
	AN	6,475,725	11/5/2002	Reiter et al.			
	AO	6,693,075	2/17/2004	Nelsestuen			
	AP	6,747,003	6/8/2004	Nelsestuen			
	AQ	6,762,286	7/13/2004	Nelsestuen			
	AR	6,903,069	6/7/2005	Pingel et al.			
	AS	2003/0100506	11/18/2002	Nelsestuen			
	AT	2003/0100740	11/15/2002	Persson et al.			
	AU	2003/0104978	9/13/2001	Persson et al.			
	AV	2003/0211094	12/30/2002	Nelsestuen			
	AW	2003/0211460	12/30/2002	Nelsestuen			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner	Desig.	Document	Publication	Country or	Class	Subclass	Translation

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09531-016002	Application No. 10/031,005
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR § 1.98(b))		Applicant Gary L. Nelsestuen	
		Filing Date October 29, 2001	Group Art Unit 1656

							Yes	No
	AX	WO 91/11514	8/8/1991	WIPO				
	AY	WO 92/15686	9/17/1992	WIPO				
	AZ	WO 94/27631	12/8/1994	WIPO				
	AAA	WO 96/00577	1/11/1996	WIPO				
	ABB	WO 98/32466	7/30/1998	WIPO				
	ACC	WO 98/35026	8/13/1998	WIPO				
	ADD	WO 99/03498	1/28/1999	WIPO				
	AEE	WO 99/03887	1/28/1999	WIPO				
	AFF	WO 99/66031	12/23/1999	WIPO				
	AGG	WO 00/26230	5/11/2000	WIPO				
	AHH	WO 00/26354	5/11/2000	WIPO				
	AII	WO 00/28065	5/18/2000	WIPO				
	AJJ	WO 00/54787	9/21/2000	WIPO				
	AKK	WO 00/66753	11/9/2000	WIPO				
	ALL	WO 01/83725	11/8/2001	WIPO				
	AMM	WO 02/02764	1/10/2002	WIPO				
	ANN	WO 02/03075	1/10/2002	WIPO				
	AOO	WO 02/077218	10/3/2002	WIPO				
	APP	WO 02/22776	3/21/2002	WIPO				
	AQQ	WO 02/29025	4/11/2002	WIPO				
	ARR	WO 02/38162	5/16/2002	WIPO				
	ASS	WO 03/027147	4/3/2003	WIPO				
	ATT	WO 03/037932	5/8/2003	WIPO				
	AUU	WO 03/055512	7/10/2003	WIPO				
	AVV	WO 03/093465	11/13/2003	WIPO				
	AWW	WO 2004/029091	4/8/2004	WIPO				
	AXX	WO 2004/083361	9/30/2004	WIPO				
	AYY	EP 0 370 205	5/30/1990	EPO				
	AZZ	EP 0 512 011	11/11/1992	EPO				

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09531-016002	Application No. 10/031,005
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))		Applicant Gary L. Nelsestuen	
		Filing Date October 29, 2001	Group Art Unit 1656

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AAAA	Bharadwaj et al., "Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity," J. Biol. Chem., 1996, 271:30685-30691
	ABBB	Bjoern et al., "Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine," J. Biol. Chem. 1991, 266(17):11051-11057
	ACCC	Chang et al., "Engineered recombinant factor VII Q217 variants with altered inhibitor specificities," Biochemistry 1999, 38:10940-10948
	ADDD	Chang et al., "Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B," J. Clin. Invest. 1997, 100(4), 886-892
	AEEE	Cheung et al., "Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX," Thrombosis Res. 1995, 80(5): 419-427
	AFFF	EMBL Accession No. AF465270 (2/2/2003)
	AGGG	UNIPROT Accession No. P22457 (8/1/1991)
	AHHH	Dickinson et al., "Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa," J. Mol. Biol. 1998, 277:959-971
	AIII	Dickinson et al., "Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa," Proc. Natl. Acad. Sci. 1996, 93:14379-14384
	AJJJ	Hedner et al., "NovoSeven as a universal haemostatic agent," Blood Coagulation & Fibrinolysis 2000:11:107-111
	AKKK	Higashi et al., "Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity," J. Biol. Chem. 1996, 271(43):26569-26574
	ALLL	Huang et al., "Substrate Recognition by Tissue Factor-Factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X" J. Biol. Chem. 1996, 271(36):21752-21757
	AMMM	Iino et al., "Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII," Archives of Biochemistry and Biophysics 1998, 352(2):182-192
	ANNN	Iakhiaev et al., "The Role of Catalytic Cleft & Exosite Residues of Factor VIIa for Complex Formation with Tissue Factor Pathway Inhibitor" Thromobsis & Haemostasis 2001, 85:458-463
	AOOO	Jin et al., "Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity," Biochemistry 1999, 38:1185-1192
	APPP	Jin et al., "Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity," J. Mol. Biol. 2001, 307:1503-1517
	AQQQ	Kelly et al., "Ca^{2+} binding to the first epidermal growth factor module of coagulation factor VIIa is important for cofactor interaction and proteolytic function," J. Biol. Chem. 1997, 272(28):17467-17472
	ARRR	Kemball-Cook et al., "Coagulation Factor VII Gln^{100} Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function," J. Biol. Chem. 1998, 273(14):8516-8521

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09531-016002	Application No. 10/031,005
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Gary L. Nelsestuen	
		Filing Date October 29, 2001	Group Art Unit 1656

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	ASSS	Leonard et al., "Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII," J. Biol. Chem. 2000, 275(45):34894-34900
	ATTT	Mayer, "Ultra-early hemostatic therapy for intracerebral hemorrhage," Stroke 2003, 34:224-229
	AUUU	Neuenschwander et al., "Alteration of the substrate and inhibitor specificities of blood coagulation," Biochemistry 1995, 34:8701-8707
	AVVV	Persson et al., "Ca^{2+} binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity," J. Biol. Chem. 1997, 272(32):19919-19924
	AWWW	Persson, "Characterization of the interaction between the light chain of factor VIIa and tissue factor," FEBS Letters 1997, 413:359-363
	AXXX	Petersen et al., "Binding of Zn^{2+} to a Ca^{2+} loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor," Protein Science 2000, 9:859-866
	AYYY	Petrovan et al., "Role of residue Phe^{225} in the cofactor-mediated, allosteric regulation of the serine protease coagulation factor VIIa," Biochemistry 2000, 39:14457-14463
	AZZZ	Petrovan et al., "Residue Met^{156} contributes to the labile enzyme conformation of coagulation factor VIIa," J. Biol. Chem. 2001, 276(9):6616-6620
	AAAAA	Shobe et al., "Regulation of the catalytic function of coagulation factor VIIa by a conformational linkage of surface residue Glu 154 to the active site," Biochemistry 1999, 38:2745-2751
	ABBBB	Shobe et al., "Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking," J. Biol. Chem. 1999, 274(34):24171-24175
	ACCCC	Sridhara et al., "Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor," Amer. J. Hemotology 1996, 53:66-71
	ADDDD	Zhang et al., "Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant," J. Mol. Biol. 1999, 285(5):2089-2104

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	